Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
Abstract With the introduction of novel therapeutic agents, survival in Multiple Myeloma (MM) has increased in recent years.However, drug-resistant clones inevitably arise and lead to disease progression and death.The current International Myeloma Working Group response criteria are broad and make it difficult to clearly designate resistant and res